A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
The DNBSEQ-T7 ultra-high-throughput sequencer, metagenomic sequencing kit for coronaviruses, and 2019-nCoV RT-qPCR kit have received authorization from China's NMPA.
The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.
MGI Tech will market Pillar Biosciences' Onco/Reveal NGS panels alongside its high-throughput, automated library prep systems outside the US.
MGI received medical device certification clearance for its MGISEQ-200 and MGISEQ-2000 instruments.
The company recently released the MGISEQ-2000, MGISEQ-200, and MGIFLP sequencing platforms, as well as the MGIUS-R3 robotic ultrasound system.
The new BGISEQ-50, a smaller version of the BGISEQ-500, will have research and clinical applications, and BGI plans to register it with the CFDA, too.